Elicio Therapeutics (ELTX) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company developing novel immunotherapies for cancer, focusing on mKRAS-positive pancreatic, colorectal, lung, and other cancers.

• Proprietary AMP technology enhances T cell responses by targeting lymph nodes, aiming for durable cancer immunosurveillance.

• Lead candidate ELI-002 7P is in Phase 2 for mKRAS-driven pancreatic cancer, with plans to expand to other indications.

• Pipeline includes preclinical candidates for b-raf and p53-mutated cancers.

• Completed a reverse merger in 2023, now headquartered in Boston, MA.

Financial performance and metrics

• Audited financial statements for the year ended December 31, 2025, are incorporated by reference.

• Auditor's report includes a going concern explanatory paragraph.

Use of proceeds and capital allocation

• Net proceeds intended for working capital, R&D, business expansion, strategic transactions, and general corporate purposes.

• Pending use, proceeds may be invested in investment-grade, interest-bearing securities.